ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2900

The Incidence and Prevalence of Systemic Sclerosis in Northwestern Part of Turkey

Omer Nuri Pamuk1, Mehmet Ali Balci2, Salim Donmez3 and Gulsum Emel Pamuk4, 1Rheumatology, Department of Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, Edirne, Turkey, 2Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, 3PsART study group, Ankara, Turkey, 4Hematology, Trakya University Medical Faculty, Edirne, Turkey

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic sclerosis (SSc) is a multisystem, chronic, autoimmune disease. In this hospital based study, we aimed to evaluate the prevalence and incidence of SSc in our region.

Methods: During the 2003-2015, SSc patients diagnosed in our Department were included. Our Department is the only tertiary center of Rheumatology in this northwestern part of Turkey. The diagnosis of SSc was performed according to ACR 1980 criteria. Clinical and demographical data about SSc patients were obtained from medical charts.

Results: Of the 161 patients (146F, 15M) carrying the diagnosis the diagnosis of SSc, During the study period, the mean annual incidence rate was 2.16/100,000 for SSc. The annual incidence of SSc in women was 3.98/100,000, and in men was 0.4/100,000. In second period of study (2010-2015 vs. 2003-2009), general incidence rate increased especially in males (from 0.27 to 0.53/100,000). By December 2014, the overall point prevalence of SSc in our region was 23.2/100000 in population aged ˃16 years. The point prevalence in women (42.8/100000) was higher than the point prevalence in men (4.1/100000). Among women, SSc was more prevalent in the fourth and fifth decades of life. Among men, the peak orevalence was in the sixth decade of life. The period prevalence of SSc was 25.9/100000. The period prevalence in women was 47.7/100000 and in men it was 4.8/100000. The median age at diagnosis was 49 (21–84) years for SSc patients. 123 patients (76.4%) had limited cutaneous, 35 patients (22.4%) had diffuse SSc and 2 patients (1.2%) had sine scleroderma. Interstitial lung disease was detected in 55 patients (34.2%), pulmonary hypertension in 69 patients (42.9%), digital ulcers in 46 patients (28.6), arthritis in 47 patients (29.2%) and renal crisis in 2 patients.ANA positivity was detected in 90.1% of patients. Anti-centromer was positive in 26.7% of patients, anti-Scl-70 was positive in 28% of patients, anti-Ro in 15% of patients and anti-RNP in 11.9% of patients. The median follow-up time of all SSc patients was 48 months (3-160). 20 patients with SSc were died (16 females, 4 males). 5 and 10-years survivals of patients with SSc were 93.6% and 83.1% respectively. Univariate analysis revealed that, male sex (p=0.018), age older than >65 years at the time of diagnosis (p=0.016), pulmonary hypertension (p=0.005), digital ulcer (p=0.034), diffuse cutaneous disease (p=0.032), low level FVC (p=0.023) and anti-Scl-70 positivity (p=0.05) were poor prognostic factors. Multivariate Cox regression analysis showed that, male sex (p=0.05) and pulmonary hypertension (p=0.032) were independent poor prognostic factors in our SSc patients.

Conclusion: In conclusion, we found in our study from northwestern part of European Turkey that SSc prevalence (23.2/100,000) and incidence (2.1/100,000) is similar to data form European countries and US studies.


Disclosure: O. N. Pamuk, None; M. A. Balci, None; S. Donmez, None; G. E. Pamuk, None.

To cite this abstract in AMA style:

Pamuk ON, Balci MA, Donmez S, Pamuk GE. The Incidence and Prevalence of Systemic Sclerosis in Northwestern Part of Turkey [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/the-incidence-and-prevalence-of-systemic-sclerosis-in-northwestern-part-of-turkey/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-incidence-and-prevalence-of-systemic-sclerosis-in-northwestern-part-of-turkey/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology